Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03568188 | Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer(FOCALE) | completed | Phase 2 | 174 | Hospices Civils de LyonOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06267729 | Study of AZD0754 in Participants With Metastatic Prostate Cancer(APOLLO) | recruiting | Phase 1 / Phase 2 | 60 | AstraZenecaINDUSTRY | 3 | Feb 23, 2026 |
| clinicaltrials |
| NCT06378346 | GU-01: Glycyrrhizin in Prostate Cancer(GU-01) | recruiting | Phase 2 | 60 | University of Illinois at ChicagoOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | recruiting | Phase 2 | 58 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT00809991 | Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate | completed | Phase 2 | 91 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06111313 | The University of Miami Adapt (UAdapt) Trial | recruiting | Phase 2 | 130 | University of MiamiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03421782 | Fatigue Interventions in Cancer (Exercise Intervention) | completed | Phase 2 | 126 | University of UtahOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06661902 | Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial(BURN) | completed | Phase 1 / Phase 2 | 350 | University of WashingtonOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06990542 | Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer(RadTARGET) | recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01543659 | Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02274779 | Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer(OLIGOPELVIS) | completed | Phase 2 | 74 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04754191 | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer(ENCORE) | active not recruiting | Phase 2 | 34 | University of UtahOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial(REVELUTION) | active not recruiting | Phase 2 | 94 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01517451 | Radiation and Androgen Ablation for Prostate Cancer | completed | Phase 1 / Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06591819 | Hypofractionated WPPT With HDR Boost | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07325721 | Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 46 | Medical University of South CarolinaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05366842 | Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care | terminated | Phase 2 | 3 | Johns Hopkins UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02312401 | Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy | active not recruiting | Phase 2 | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06397703 | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | recruiting | Phase 2 | 392 | NYU Langone HealthOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07210086 | Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) | recruiting | Phase 2 | 50 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03338790 | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer(CheckMate 9KD) | completed | Phase 2 | 292 | Bristol-Myers SquibbINDUSTRY | 11 | Jan 27, 2026 | clinicaltrials |
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer(PSMA SBRT-SIB) | recruiting | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03503344 | Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer(PILLAR) | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | active not recruiting | Phase 2 | 135 | Swiss Cancer InstituteOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT05038332 | Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) | recruiting | Phase 2 | 136 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03556904 | FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) | completed | Phase 2 | 14 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | terminated | Phase 2 | 54 | ExelixisINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06391034 | Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | recruiting | Phase 2 | 161 | Robert Bok, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06970119 | A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 55 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06084338 | Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | recruiting | Phase 2 | 60 | VA Office of Research and DevelopmentFED | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03809000 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery(STEEL) | active not recruiting | Phase 2 | 188 | RTOG Foundation, Inc.OTHER | 2 | Dec 30, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Feb 24, 2026source: clinicaltrials